Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.

NCT01507480 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT01507480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01507480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
December 31, 2012
Enrollment
42 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rendu osler disease, telangiectasia, hereditary hemorrhagic